SABCS' 15neratinib AFTER 1 yr herceptin continues to improve disease free survival--
 

results hold up@3yrs





Neratinib Keeps Benefiting Herceptin-Treated Breast Cancer

New results from the ExteNET study of the investigational drug neratinib after adjuvant trastuzumab confirm a benefit of the agent beyond the previously reported 2-year results, researchers reported here. "The 3-year exploratory analysis is consistent with previously reported results at 2 years and supports that neratinib significantly improves invasive disease-free survival," said principal investigator Arlene Chan, MD, from the Breast Cancer Research Centre at Western Australia and Curtin University in Perth. "One of the purposes of presenting these results at this meeting was to really demonstrate to the oncology community that with ongoing follow-up — certainly to this point — we are still seeing a consistent benefit of neratinib," she added, explaining that concerns about the persistent benefit of therapy have arisen out of long-term follow-up from the HERA study of patients treated with trastuzumab.